Results for the Third Quarter 2019
Sales ended at MNOK 85.5 for the quarter (MNOK 77.6), a 10.2 % growth. Sales as of September increased by 17.6 % and ended at MOK 268.1(MNOK 228.0). Read the full report and presentation below.…
Read moreMedistim has received clearance for sale of MiraQ™ in Japan
Medistim announces that they have received confirmation from its distributor in Japan that its newest product MiraQ™ is now approved for sale. MiraQ is Medistim's newest generation of products for quality assurance within vascular and…
Read moreResults for the Second Quarter and First Half 2019
Q2 2019 is the third consecutive quarter with strong growth in both sales revenues and EBIT; 23.1 % and 70.4 % respectively. Read the full report and presentation below. Medistim Q2 19 presentation 2.quarter 2019
Read moreResults for the First Quarter 2019
Sales in the first quarter amounted to MNOK 88.7 (MNOK 74.1), a 19.7 % growth. Of the MNOK 14.6 in sales growth, MNOK 11.6 was from the US, where the sales increase in NOK was…
Read moreAnnual Report 2018
During 2018, we reached an important milestone when the final results from the 1000 patients prospective, multi-center registry study REQUEST was presented. In this study, some of the best cardiac centers in Europe, Canada, and…
Read moreResults for Fourth Quarter and Preliminary Results for Medistim for 2018
Currency neutral sales of own products increased with 25.5 % for the quarter. For 2018, currency neutral growth in sales of own products was 10.0%. EBIT for the quarter ended at MNOK 27.8 (MNOK 16.4),…
Read moreResults for the Third Quarter 2018
Sales as of September increased by 4.0 % and ended at MOK 228.0 (MNOK 219.2). Revenue from own products showed a currency neutral decline of 0.4 % for the quarter and a currency neutral growth…
Read moreREQUEST Final Results: Strengthening the Recommendation for Medistim’s Dual Technology
The objective for the REQUEST study is to document how often the combination of high-frequency ultrasound imaging (HFUS) and Transit Time Flow Measurement (TTFM) performed with Medistim's VeriQ C or MiraQ devices will change the…
Read moreResults for the Second Quarter 2018
Sales for the first half of 2018 increased by 4,7 % and ended at MNOK 150,4 (MNOK 143,5). Currency neutral growth of own products was 19,3 % for the second quarter. Operating profit (EBIT) ended…
Read moreREQUEST Interim Results: Significant Impact on Surgical Strategy with Medistim’s Devices
The objective for the REQUEST study is to document how often the combination of high-frequency ultrasound imaging (HFUS) and transit time flow measurement (TTFM) performed with Medistim’s VeriQ C or MiraQ devices will change the…
Read more